ArticleFrontiers in immunology2026
Risk of systemic rheumatic diseases in people with irritable bowel syndrome: a global-federated cohort analysis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Irritable bowel syndrome (IBS) is a prevalent disorder of gut-brain interaction increasingly linked to immune and inflammatory dysregulation. Whether IBS predisposes to systemic rheumatic diseases remains uncertain. Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network, which integrates anonymized electronic health records from more than 150 healthcare organizations and 150 million patients worldwide. Adults (≥18 years) diagnosed with IBS (≥2 visits) between 2015 and 2023 were compared with matched controls undergoing routine health evaluations without IBS. Exclusion criteria included malignancy, pre-existing systemic rheumatic diseases, and death before the index date. Propensity score matching (1:1) balanced demographics, comorbidities, psychiatric disorders, and socioeconomic factors. The primary outcome was incident systemic rheumatic disease, categorized into inflammatory arthritis (ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, gout) and connective tissue disorders (systemic lupus erythematosus, systemic sclerosis, Sjögren syndrome, dermatomyositis/polymyositis). Risk estimates were generated using the TriNetX analytic function, reporting hazard ratios with 95% confidence intervals. Sensitivity analyses included alternative definitions, extended washout periods (24 and 36 months), varying follow-up durations, active comparator cohorts, and negative controls. Cross-dataset validation was performed using the TriNetX US Collaborative Network. Results: After matching, 459966 patients were included in each cohort. Irritable bowel syndrome was associated with increased risks of ankylosing spondylitis (HR 2.57, 95% CI 2.22-2.98), psoriatic arthritis (HR 2.03, 95% CI 1.80-2.29), rheumatoid arthritis (HR 1.42, 95% CI 1.28-1.56), and gout (HR 1.34, 95% CI 1.27-1.42). Elevated risks were also observed for systemic lupus erythematosus (HR 1.84, 95% CI 1.65-2.04), Sjögren syndrome (HR 2.84, 95% CI 2.60-3.12), systemic sclerosis (HR 2.09, 95% CI 1.64-2.67), and dermatomyositis (HR 1.52, 95% CI 1.11-2.07). These associations remained across multiple sensitivity and stratified analyses. Conclusions: IBS was associated with a higher risk of diverse systemic rheumatic diseases. Further studies are warranted to clarify the mechanisms underlying these observed associations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.